<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>CytomX Therapeutics, Inc.</title>
    <link>https://www.biospace.com/employer/396997/cytomx-therapeutics-inc</link>
    <description>CytomX Therapeutics, Inc.</description>
    <language>en-US</language>
    <lastBuildDate>Thu, 06 Feb 2020 18:57:21 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/396997/cytomx-therapeutics-inc.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>BioSpace Movers &amp; Shakers: Feb. 7</title>
      <link>https://www.biospace.com/biospace-movers-and-shakers-feb-7</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Pharma and biotech companies strengthen their leadership teams and boards with this weeks appointments.</description>
      <pubDate>Thu, 06 Feb 2020 18:57:21 GMT</pubDate>
      <guid>https://www.biospace.com/biospace-movers-and-shakers-feb-7</guid>
    </item>
    <item>
      <title>Astellas and CytomX Strike Immuno-Oncology Deal Worth More than $1.6 Billion</title>
      <link>https://www.biospace.com/astellas-and-cytomx-strike-immuno-oncology-deal-worth-more-than-1-6-billion</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Under terms of the agreement, Astellas will make an upfront cash payment of $80 million to CytomX.</description>
      <pubDate>Tue, 24 Mar 2020 11:18:41 GMT</pubDate>
      <guid>https://www.biospace.com/astellas-and-cytomx-strike-immuno-oncology-deal-worth-more-than-1-6-billion</guid>
    </item>
    <item>
      <title>BioSpace Movers &amp; Shakers, March 27</title>
      <link>https://www.biospace.com/biospace-movers-and-shakers-march-27</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Pharma and life sciences companies from across the globe provide updates on their pipelines and business.</description>
      <pubDate>Thu, 26 Mar 2020 17:51:51 GMT</pubDate>
      <guid>https://www.biospace.com/biospace-movers-and-shakers-march-27</guid>
    </item>
    <item>
      <title>Clinical Catch-Up: November 2-6</title>
      <link>https://www.biospace.com/clinical-catch-up-november-2-6</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.</description>
      <pubDate>Fri, 06 Nov 2020 15:19:06 GMT</pubDate>
      <guid>https://www.biospace.com/clinical-catch-up-november-2-6</guid>
    </item>
    <item>
      <title>BioSpace Movers &amp; Shakers, Oct. 8</title>
      <link>https://www.biospace.com/biospace-movers-and-shakers-oct-8</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers &amp; Shakers.</description>
      <pubDate>Thu, 07 Oct 2021 16:17:14 GMT</pubDate>
      <guid>https://www.biospace.com/biospace-movers-and-shakers-oct-8</guid>
    </item>
    <item>
      <title>BioSpace Movers &amp; Shakers, Feb. 11</title>
      <link>https://www.biospace.com/biospace-movers-and-shakers-feb-11</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers &amp; Shakers.</description>
      <pubDate>Thu, 10 Feb 2022 18:28:47 GMT</pubDate>
      <guid>https://www.biospace.com/biospace-movers-and-shakers-feb-11</guid>
    </item>
    <item>
      <title>Clinical Catch-Up: 3's the Charm for Pfizer-BioNTech Vaccine in Kids &amp; More</title>
      <link>https://www.biospace.com/clinical-catch-up-may-23-27</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.</description>
      <pubDate>Fri, 27 May 2022 14:59:49 GMT</pubDate>
      <guid>https://www.biospace.com/clinical-catch-up-may-23-27</guid>
    </item>
    <item>
      <title>Following Breast Cancer Fail, CytomX Slashes Workforce by 40% - UPDATED</title>
      <link>https://www.biospace.com/cytomx-breast-cancer-drug-fails-in-two-cohorts-trial-discontinued</link>
      <dc:creator>Vanessa Doctor, RN</dc:creator>
      <description>CytomX Therapeutics is shifting its focus to preclinical and early clinical studies, emphasizing alliances and slashing its workforce by about 40% to extend cash flow to 2025.</description>
      <pubDate>Thu, 07 Jul 2022 05:23:33 GMT</pubDate>
      <guid>https://www.biospace.com/cytomx-breast-cancer-drug-fails-in-two-cohorts-trial-discontinued</guid>
    </item>
    <item>
      <title>Regeneron, CytomX Ink Potentially $2B Bispecific Immunotherapy Deal (Updated)</title>
      <link>https://www.biospace.com/regeneron-cytomx-ink-deal-worth-up-to-2-billion-to-develop-conditional-bispecific-antibodies</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Regeneron and CytomX Therapeutics inked a deal valued at up to $2 billion to develop next-generation bispecific immunotherapies for cancer, the companies announced Thursday.</description>
      <pubDate>Thu, 17 Nov 2022 15:18:20 GMT</pubDate>
      <guid>https://www.biospace.com/regeneron-cytomx-ink-deal-worth-up-to-2-billion-to-develop-conditional-bispecific-antibodies</guid>
    </item>
    <item>
      <title>Top Biotech Licensing Deals of Q1 2023</title>
      <link>https://www.biospace.com/top-biotech-licensing-deals-from-2023</link>
      <dc:creator>Jia Jie Chen</dc:creator>
      <description>There have already been several big biotech licensing deals in Q1. See inside for some of this quarter's biggest licensing deals — from the surprising and pivotal to the lucrative and consequential.</description>
      <pubDate>Wed, 29 Mar 2023 18:32:01 GMT</pubDate>
      <guid>https://www.biospace.com/top-biotech-licensing-deals-from-2023</guid>
    </item>
  </channel>
</rss>
